Get the Daily Brief
Latest Biotech News
AI discovery surge: Insilico’s $888M oncology pact and 1910’s PEGASUS model
AI drug discovery momentum continued with an $888 million R&D collaboration between Insilico Medicine and Servier to identify oncology candidates, and publication of PEGASUS by AI biotech 1910, an...
New enabling tools: Illumina's multiomics cloud and St. Jude’s CHANGE‑seq‑BE
Illumina launched Connected Multiomics, a cloud‑based software platform that integrates sequencing, AI analytics and workflows to accelerate multiomic studies for customers, positioning the...
CDC slashes routine childhood shots: U.S. schedule trimmed to 11
Federal health officials moved this week to reduce the number of vaccines the U.S. routinely recommends for children, cutting the schedule from 17 to 11. The change, announced by HHS and...
Amgen snaps up Dark Blue: $840M deal to add protein degrader for leukemia
Amgen agreed to acquire Oxford spinout Dark Blue Therapeutics for up to $840 million to add a preclinical small-molecule program that degrades MLLT1/3 proteins implicated in certain acute myeloid...
Lilly returns to Nimbus: $1.3B pact for oral obesity program
Eli Lilly expanded its metabolic pipeline by partnering again with AI-powered Nimbus Therapeutics on a small-molecule program aimed at treating obesity and related cardiometabolic disorders. Lilly...
Alumis’ TYK2 pill clears pivotal tests — prepares FDA filing
Alumis reported that envudeucitinib, its selective oral TYK2 inhibitor, met primary and key secondary endpoints in two Phase 3 psoriasis trials and said it will seek regulatory approval later this...
Arrowhead RNAi plus tirzepatide shows early fat-loss gains — Phase 1 results
Arrowhead Pharmaceuticals released interim Phase 1/2 data showing its RNAi candidate ARO-INHBE, given with Lilly’s tirzepatide (Zepbound), produced larger reductions in weight, visceral fat and...
Moderna files for mRNA flu shot: regulators in US, EU, Canada, Australia targeted
Moderna submitted regulatory applications for mRNA‑1010, its mRNA‑based seasonal influenza vaccine, seeking approval for use in people 50 and older across the U.S., Europe, Canada and Australia....
Pfizer taps Cartography to map tumor‑selective antigens — deal could top $865M
Pfizer struck a discovery collaboration with Cartography Biosciences to use Cartography’s ATLAS and SUMMIT platforms to identify tumor‑selective antigens for an undisclosed oncology indication....
Deep Intelligent Pharma raises $50M to scale AI clinical‑trial automation
Singapore‑based Deep Intelligent Pharma closed a $50 million Series D to advance its AI-driven clinical‑trial automation platform that the company describes as breaking development into...
St. Jude unveils CHANGE‑seq‑BE: sensitive genome‑wide base‑editor profiling
Researchers at St. Jude Children’s Research Hospital published CHANGE‑seq‑BE, a resource‑efficient, unbiased method to detect genome‑wide off‑target activity of base editors. The team demonstrated...
CRISPR–Cas3 produces long deletions, knocks down TTR in mice — distinct from Cas9
A preclinical study demonstrated that CRISPR–Cas3, delivered by lipid nanoparticles, can generate directional, long‑range deletions at the TTR locus in mice, achieving ~48.7% hepatic editing and...
Amgen snaps up Dark Blue Therapeutics — $840M deal to bolster AML degrader
Amgen agreed to acquire Oxford University spinout Dark Blue Therapeutics for up to $840 million to add a preclinical small‑molecule degrader aimed at MLLT1/3‑driven acute myeloid leukemia (AML)....
Variant Bio teams with Boehringer — up to $120M for kidney‑target discovery
Variant Bio and Boehringer Ingelheim struck a research collaboration and license to discover novel targets for kidney and cardiorenal disease, with Variant eligible for upfront and milestone...
Insilico inks $888M oncology pact with Servier after IPO
Insilico Medicine signed a multiyear R&D collaboration with France’s Servier valued at as much as $888 million to apply Insilico’s AI discovery platform to oncology programs, following the...
Pfizer bets on tumor‑selective antigens — up to $865M pact with Cartography
Pfizer signed a multiyear discovery collaboration with Cartography Biosciences to identify tumor‑selective antigens, a deal that could be worth up to $865 million if all options and milestones are...
Arrowhead RNAi obesity candidates show early fat‑loss — moving to Phase 2
Arrowhead Pharmaceuticals reported early clinical signals from RNAi candidates targeting obesity biology, including ARO‑INHBE, which produced meaningful fat‑loss when dosed in combination with Eli...
Zenas meets Phase III goal in IgG4‑RD — investors punish cross‑trial comparison
Zenas Biopharma’s obexelimab hit the primary endpoint in the Phase III Indigo trial for immunoglobulin G4‑related disease but the magnitude of benefit compared unfavorably to Amgen’s recently...
Novo launches Wegovy pill — $25 insured, $149 cash list
Novo Nordisk officially launched an oral formulation of its GLP‑1 obesity drug Wegovy in the U.S., listing insured patient copays as low as $25 per month and a cash price of $149 for starting...
Appeals court blocks NIH 15% indirect‑cost cap — injunction remains
A U.S. Court of Appeals affirmed a lower court injunction preventing the National Institutes of Health from imposing a 15% cap on indirect cost reimbursements to universities and research...